Back to Results
First PageMeta Content
Chemistry / Body shape / Organochlorides / Anorectics / Nutrition / Management of obesity / Sibutramine / Rimonabant / Orlistat / Health / Medicine / Obesity


Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI Work Package 5: Report 2:b:i Benefit - Risk Wave 2 Case Study Report: Rimonabant
Add to Reading List

Document Date: 2014-07-16 01:09:14

Open Document

File Size: 2,43 MB

Share Result on Facebook

Company

Aventis / Sanofi / /

Continent

Europe / /

Country

United States / /

Event

Product Issues / Product Recall / Natural Disaster / /

IndustryTerm

visual presentation tool / food intake / treatment of obesity / /

MarketIndex

BRAT / /

MedicalCondition

nutritional obesity / non-fatal stroke / Two Diabetes Mellitus / non-fatal myocardial infarction / diabetes mellitus / obesity / hypersensitivity / cardiac arrest / Depression / cardiovascular diseases / e.g. diabetes / /

MedicalTreatment

adjunctive therapy / /

Organization

Risk Ratio CHMP Committee for Medicinal Products / Food and Drug Administration / European Medicines Agency / European Commission / FDA / Committee for Medicinal Products for Human Use / European Union / /

Person

Georgy Genov Ian Hirsch Kimberley / Edmond Chan Georgy Genov Ian / Ian Hirsch Kimberley Hockley Marilyn / Isa George Quartey / Kimberley Hockley Marilyn Metcalf Shahrul / Billy Amzal Edmond Chan Georgy / /

Product

XENICAL / marketing authorization / MERIDIA / /

RadioStation

Wave 2 / Wave 1 / /

Technology

Simulation / /

URL

www.imi.europa.eu / www.imiprotect.eu / /

SocialTag